Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Explore the Medtronic development journey of irreversible electroporation (IRE), pulsed field ablation (PFA), and the science behind the novel cardiac ablation technology.
View the PULSED AF secondary analysis now.
Caution: Investigational device, limited to investigational use only. Not available for sale in the U.S. The PULSED AF clinical evidence has not been evaluated by the FDA.
PULSED AF was a global, paired single arm, prospective, non-randomized study that evaluated the safety and effectiveness of the PulseSelect™ pulsed field ablation system for the treatment of patients with paroxysmal (PAF) or persistent (PsAF) atrial fibrillation. The study was conducted in nine countries across 41 sites and 67 operators. The primary analysis included 300 symptomatic AF patients, refractory to class I or III antiarrhythmic drugs, of which 150 were paroxysmal and 150 were persistent. 96% (287) of patients completed 12-month follow-up.
Acute pilot results of the PULSED AF trial were first presented as a late-breaking clinical trial at Heart Rhythm Society (HRS) in May 2020 by Dr. Atul Verma. This was the first in-human evaluation of the novel pulsed field ablation system from Medtronic to measure safety and acute effectiveness in 38 patients with paroxysmal or persistent atrial fibrillation followed for 30 days.
Read more about the PULSED AF pilot trial.
Therapy delivery with no phrenic nerve injury, esophageal injury, or stroke
Ostial and antral isolation
Maximum esophageal temperature of 36.14 ± 0.34° C
100% acute electrical isolation in 152 pulmonary veins
Average electrode temperature rise of 2.1 ± 2.2º C at one second post-ablation
Medtronic has completed extensive preclinical and clinical work since 2006 to understand the safety and efficacy of IRE for cardiac ablation.
Listen to Professor Damijan Miklavčič explain the fundamentals of electroporation and the phenomenon of nonselective transmembrane transport across a cell membrane.
Watch Damijan Miklavčič, Ph.D., Atul Verma, M.D., and Khaldoun Tarakji, M.D. discuss the fundamentals of electroporation and how it applies to pulsed field ablation.
Log in to Medtronic Academy to view the recording.
Watch Damijan Miklavčič, Ph.D., David Haines, M.D., Atul Verma, M.D., and Khaldoun Tarakji, M.D. discuss the fundamental biology of tissue selectivity, preclinical characterization of collateral tissue effects with PFA technology, and the clinical PULSED AF pilot acute safety and pivotal study design.
Watch John Hummel, M.D., Atul Verma, M.D., and Khaldoun Tarakji, M.D. review the PULSED AF procedural workflow and the long-term results of the PULSED AF pivotal trial.
Verma A, Haines DE, Boersma LV, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. May 9, 2023;147(19):1422–1432.
Verma A, Haines DE, Boersma LV, et al. Influence of Monitoring and Atrial Arrhythmia Burden on Quality of Life and Healthcare Utilization in Patients Undergoing Pulsed Field Ablation: A Secondary Analysis of the PULSED AF Trial. Heart Rhythm. Published online May 2023.
Verma A, Boersma L, Haines DE, et al. First-in-Human Experience and Acute Procedural Outcomes Using a Novel Pulsed Field Ablation System: The PULSED AF Pilot Trial. Circ Arrhythm Electrophysiol. January 2022;15(1):e010168.